| Bioactivity | CP-544439 is a potent and orally active matrix metalloproteinase-13 (MMP-13) inhibitor with an IC50 of 0.75 nM[1][2]. |
| In Vivo | In vivo studies using a hamster model, in which the cartilage collagen degradation was induced by intra-articular injection of recombinant human MMP-13, demonstrated that oral administration of CP-544439 inhibits degradation of the cartilage collagen with an ED50 of 14 mg/kg and efficacious plasma concentrations ranging from 0.5 to 1.0 g/ml[1]. |
| Name | CP-544439 |
| CAS | 230954-09-3 |
| Formula | C18H19FN2O6S |
| Molar Mass | 410.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Dalvie D, et al. Metabolism distribution and excretion of a matrix metalloproteinase-13 inhibitor, 4-[4-(4-fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide (CP-544439), in rats and dogs: assessment of the metabolic profil [2]. Reiter LA, et al. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1. Bioorg Med Chem Lett. 2004;14(13):3389-3395. |